IMI Innovative medicine initiative - Future topics

To give potential applicants as much time as possible to form consortia and prepare their proposals, IMI regularly publishes information on possible future topics well in advance of the official Call launch.

Future Call dates

IMI’s next Calls for proposals are currently planned for 26/06/2019. This date is indicative and may change.

IMI2 - Calls 18 & 19

The following topics are under consideration for inclusion in the next IMI Calls for proposals (IMI2 - Calls 18 and 19, which will be launched at the same time). These topics are now at an advanced stage of development and we hope that these drafts will allow potential applicants to start working actively on proposals and forming consortia. Draft topic texts are subject to consultations involving IMI's States Representatives Group, Scientific Committee, and the European Commission. They must also be approved by the IMI Governing Board. Depending on the results of the consultations and approval process, the final topic text may differ significantly from the draft versions initially published here, and applicants should always base their proposals on the final, approved topic texts which will be published when the Call is officially launched. Furthermore, although it is unlikely at this stage, it is possible that a draft topic may be postponed to a future Call or dropped entirely.

Source: IMI

Publication of a review on decision models of prediabetes populations

The joint work of the RHAPSODY partners UOXF, UMCG and AOU TO resulted in the publication of an article in the journal Diabetes, Obesity and Metabolism entitled Decision models of prediabetes populations: A systematic review.

RHAPSODY outcomes

We are happy to announce a new page available on our website, continously informing about our project outcomes such as publishable report summaries, peer-reviewed publications etc. Enjoy browsing!

Database on Funding Activities for Personalised Medicine (PM) Research Has Been Launched

The International Consortium for Personalised Medicine (ICPerMed) database, launched on 5 July 2018, gives an overview on the actions in the field of personalised medicine performed in the ICPerMed member states and may assist interested users in finding suitable funding opportunities and information about potential funders in their respective country and/or region.

The access to the data requires simple registration here.

The first ICPerMed Conference ‘Personalised Medicine in Action’ will take place on 20-21 November 2018 in Berlin, Germany. Registration is now open.

Sources: ICPerMed, Euresearch

PhD positions in Co-Fund project on Personalized medicine in chronic diseases with a focus on diabetes

The University Medical Center Groningen, the Netherlands, is about to start a H2020 supported Co-Fund project on Personalized medicine in chronic diseases with a focus on diabetes. The project is an educational programme where PhD Fellows are going to be trained on the topic of personalized medicine mainly in diabetes. They will be offered an attractive teaching programme on personalized medicine and have the opportunity to obtain a PhD in 4 years.
PhD fellows who will be trained should come from outside the Netherlands to enhance mobility of students in Europe and beyond. Students from all parts of the world are thus eligible. We will start the program in September and we have now started to recruit candidates. Students with a background in medicine, biology, epidemiology, pharmacy etc can apply for a position.
More information can be found on the UMCG website and on the application page.

Show more posts

Stacks Image p6729_n47
Stacks Image p6729_n398
Stacks Image p6729_n51
Stacks Image p6729_n349
This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking (www.imi.europa.eu) under grant agreement No 115881. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

This work is supported by the Swiss State Secretariat for Education‚ Research and Innovation (SERI) under contract number 16.0097-2.

The opinions expressed and arguments employed herein do not necessarily reflect the official views of these funding bodies.